Country: Kanada
Bahasa: Inggeris
Sumber: Health Canada
LEVOFLOXACIN
STERIMAX INC
J01MA12
LEVOFLOXACIN
5MG
SOLUTION
LEVOFLOXACIN 5MG
INTRAVENOUS
100ML/250ML
Prescription
QUINOLONES
Active ingredient group (AIG) number: 0131663001; AHFS:
APPROVED
2016-12-22
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr LEVOFLOXACIN IN 5% DEXTROSE INJECTION Levofloxacin 5 mg / mL Sterile solution for intravenous infusion Antibacterial Agent J01MA12 Levofloxacin Submission Control Number: 270610 SteriMax Inc. 2770 Portland Drive Oakville, ON L6H 6R4 Date of Initial Authorization: December 22, 2016 Date of Revision: May 16, 2023 _LEVOFLOXACIN IN 5% DEXTROSE INJECTION Page 2 of 75_ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS 05/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics ................................................................................................................... 6 1.2 Geriatrics ................................................................................................................... 6 2 CONTRAINDICATIONS ................................................................................................. 6 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 6 4 DOSAGE AND ADMINISTRATION ................................................................................. 7 4.1 Dosing Considerations .............................................................................................. 7 4.2 Recommended Dose and Dosage Adjustment ......................................................... 7 4.4 Administration .......................................................................................................... 9 4. Baca dokumen lengkap